Understand the source comparison
How to Use Peptides for Rotator Cuff: Treatment Comparison
BPC-157 (Body Protection Compound) Stimulates VEGF and fibroblast proliferation; accelerates collagen type I deposition in tendons 250–500mcg daily, 4–6 weeks Subcutaneous, upper deltoid or arm within 5–8cm of injury Most evidence for tendon-specific repair; s
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157 (Body Protection Compound)
- Stimulates VEGF and fibroblast proliferation; accelerates collagen type I deposition in tendons
- 250–500mcg daily, 4–6 weeks
- Subcutaneous, upper deltoid or arm within 5–8cm of injury
- Most evidence for tendon-specific repair; stable at refrigerated temps for 28 days post-reconstitution
- TB-500 (Thymosin Beta-4)
- Upregulates actin polymerization and cell migration to injury sites; reduces inflammation
- 2–2.5mg twice weekly (loading), then weekly (maintenance)
- Subcutaneous or intramuscular, any site (systemic distribution)
- Broader anti-inflammatory effects; more expensive per dose; less research on isolated rotator cuff injuries
- Combination (BPC-157 + TB-500)
- Synergistic collagen synthesis (BPC-157) + cell migration/inflammation control (TB-500)
- BPC 250mcg daily + TB 2mg twice weekly
- Separate injections, same proximity window
- Used in advanced protocols; no head-to-head trials vs monotherapy; higher total cost
- BPC-157 remains the most studied peptide for tendon repair, with mechanistic data showing direct effects on collagen architecture. TB-500 offers complementary benefits but lacks the targeted tendon research that BPC-157 has accumulated. Combination therapy may be appropriate for severe partial tears or post-surgical recovery but isn't necessary for mild-to-moderate injuries.